Saturday 17 October 2026 Export NXTC’s income statement to Excel — free account

NextCure, Inc.

In the quarter to June 2026, EPS grew 75.2% and free cash flow grew 57.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

6.24 0.64 −9.30%

Follow NXTC

Alert me

Market cap: $31.5M
P/E: 0.0×
Fwd P/E: −2.4×
Dividend yield: —
F-score: n/a
Altman Z: 14.11
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.71

Total sells 0.18

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	2	—	—	—
Sell	—	—	—	—	—	—	—	—	—	1	—	—

Insider Ownership 27.87%

Capital & Financial Ratios $m

Market Cap 31.49

Revenue 27.37

Net Income (42.75)

Free Cash Flow (36.98)

Net Debt (20.09)

Current Ratio 3.47

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.39)

P/S ratio 1.21

P/B ratio 2.73

Past 5Y EPS Growth —

This Y EPS Growth 67.74%

Next Y EPS Growth 78.23%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 60.40%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 23.13%

10-year low 10-year high

P/B against its own 10 years 91.61%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	108	69	42	20
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	113	72	44	22

	2023	2024	2025	Q'26
Payables	2	5	2	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	7	10	11	6

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(34.67%)	(40.70%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’20	22	—	—	—	22

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	(10)	—	—	—
’25	(13)	(23)	(6)	(8)	(50)
’24	(13)	(10)	(11)	(7)	(41)
’23	(15)	(15)	(13)	(11)	(53)
’22	(15)	(14)	(15)	(9)	(54)
’21	(14)	(17)	(13)	(13)	(57)
’20	(11)	(12)	(16)	(6)	(45)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	(10)	—	—	—
’25	(13)	(23)	(6)	(8)	(50)
’24	(13)	(10)	(12)	(7)	(41)
’23	(15)	(15)	(13)	(11)	(54)
’22	(16)	(15)	(16)	(10)	(56)
’21	(15)	(17)	(13)	(14)	(60)
’20	(12)	(15)	(18)	(7)	(52)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.87)	(2.80)	—	—	—
’25	(4.68)	(11.29)	(3.22)	(0.81)	(19.65)
’24	(7.32)	(6.60)	(4.92)	(4.92)	(23.89)
’23	(6.96)	(7.68)	(6.12)	(6.24)	(27.01)
’22	(8.88)	(7.80)	(8.16)	(7.44)	(32.29)
’21	(7.20)	(7.80)	(7.80)	(7.32)	(30.13)
’20	3.96	(6.36)	(7.08)	(6.72)	(15.97)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	166.32	94.92	66.36	13.92	11.76	9.12	2.69	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	1,308.00	732.00	172.80	77.76	23.04	30.84	15.74
People
People	Employees	—	—	44	69	90	87	99	82	43	40
	Revenue/emp, $m	—	—	0.00	0.09	0.25	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	6	22	—	—	—	—	—
	Gross margin, %	—	0.00	0.00	100.00	100.00	0.00	0.00	—	—	—
	EBT	—	(15)	(23)	(34)	(37)	(69)	(75)	(63)	(56)	(56)
	EBT margin, %	—	0.00	0.00	(531.54)	(163.57)	0.00	0.00	0.00	0.00	0.00
	Net income	—	(15)	(23)	(34)	(37)	(69)	(75)	(63)	(56)	(56)
	Depreciation	—	1	2	3	3	7	7	3	2	2
Per share, $
Per share, $	Revenue	—	0.00	0.00	4.85	9.76	0.00	0.00	0.00	0.00	0.00
	Earnings	—	(135.65)	(199.78)	(25.81)	(15.97)	(30.13)	(32.29)	(27.01)	(23.89)	(19.65)
	Cash flow	—	(109.77)	70.04	(27.25)	(19.60)	(24.90)	(23.32)	(22.85)	(17.51)	(17.45)
	Capex	—	(75.89)	(26.84)	(2.58)	(3.11)	(1.03)	(0.92)	(0.35)	(0.20)	0.00
	Free cash flow	—	(185.67)	43.20	(29.83)	(22.71)	(25.93)	(24.23)	(23.20)	(17.71)	(17.45)
	Book value	—	136.74	1,010.33	245.90	128.07	101.45	72.49	49.34	28.09	12.29
	Shares, m	—	0	0	1	2	2	2	2	2	3
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	—	—	—	—	—
	P/S	—	—	—	139.24	10.96	—	—	—	—	—
	P/B	—	—	—	2.75	1.02	—	—	—	—	—
	EV/Sales	—	—	—	87.04	0.67	—	—	—	—	—
	EV/FCF	—	—	—	(14.17)	(0.35)	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	(13)	8	(36)	(45)	(57)	(54)	(53)	(41)	(50)
	Capex	—	(9)	(3)	(3)	(7)	(2)	(2)	(1)	0	—
	Free cash flow	—	(21)	5	(39)	(52)	(60)	(56)	(54)	(41)	(50)
Balance, $m
Balance, $m	Working capital	—	6	125	325	278	221	155	106	62	33
	Total debt	—	1	0	5	3	—	7	—	—	—
	Net debt	—	(8)	(135)	(331)	(282)	(220)	(160)	(108)	(69)	(42)
	Shareholders’ equity	—	16	115	321	294	233	168	114	65	35
Returns, %
Returns, %	ROA	—	(18.52)	(27.29)	(13.39)	(11.04)	(25.28)	(35.04)	(40.18)	(53.28)	(85.23)
	ROIC	—	(135.71)	0.00	0.00	(214.00)	(320.61)	(622.69)	(690.51)	0.00	0.00
	ROE	—	43.36	63.90	(24.58)	(11.90)	(26.33)	(37.28)	(44.49)	(61.87)	(111.23)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2020 · latest quarter Mar 2020

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ALGS Aligos Therapeutics, Inc.	$33.7M	— (loss-making)	— (loss-making)	+2,778.55% (above 0%: growing)	n/m	−59.81% (below 0%: shrinking)	100.00%	(6.80%)	Compare
ATNM Actinium Pharmaceuticals, Inc.	$33.3M	3.1×	— (loss-making)	+77,677.78% (above 0%: growing)	n/m	−4.91% (below 0%: shrinking)	100.00%	78.76%	Compare
BCTX BRIACELL THERAP	$32.8M	1.5×	—	—	n/m	+0.21% (above 0%: growing)	0.00%	0.00%	Compare
GNTA Genenta Science S.p.A. Unsponsored ADR	$32.3M	—	—	—	—	+35.94% (above 0%: growing)	0.00%	—	Compare
MGX Metagenomi Therapeutics, Inc.	$31.9M	— (loss-making)	— (loss-making)	−103.02% (below 0%: shrinking)	n/m	+7.98% (above 0%: growing)	100.00%	11,195.72%	Compare
GRDX GridAI Technologies Corp.	$31.8M	— (loss-making)	—	—	n/m	−2,640.98% (below 0%: shrinking)	(42.49%)	(15,258.21%)	Compare
NXTC NextCure, Inc.	$31.5M	— (loss-making)	— (loss-making)	+1,549.08% (above 0%: growing)	n/m	+57.23% (above 0%: growing)	0.00%	0.00%
CVM Cel-Sci Corporation	$30.6M	— (loss-making)	— (loss-making)	−62.66% (below 0%: shrinking)	n/m	−2.33% (below 0%: shrinking)	0.00%	0.00%	Compare
RNAZ TransCode Therapeutics Inc.	$30.5M	— (loss-making)	—	—	n/m	−28.79% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$32.1M	—	—	+1,357.95%	—	−3.62%	0.00%	0.00%

All 614 Biotechnology stocks →

NextCure, Inc. (NXTC) key facts

NextCure, Inc. (NXTC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NXTC traded at $6.24, a market capitalization of $31.5 million.
Return on equity was −111.2% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.